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Microarray-based prediction of clinical endpoints may be performed using
either a one-color approach reflecting mRNA abundance in absolute intensity
values or a two-color approach yielding ratios of fluorescent intensities. In this
study, as part of the MAQC-II project, we systematically compared the
classification performance resulting from one- and two-color gene-expres-
sion profiles of 478 neuroblastoma samples. In total, 196 classification
models were applied to these measurements to predict four clinical
endpoints, and classification performances were compared in terms of
accuracy, area under the curve, Matthews correlation coefficient and root
mean-squared error. Whereas prediction performance varied with distinct
clinical endpoints and classification models, equivalent performance metrics
were observed for one- and two-color measurements in both internal and
external validation. Furthermore, overlap of selected signature genes
correlated inversely with endpoint prediction difficulty. In summary, our
data strongly substantiate that the choice of platform is not a primary factor
for successful gene expression based-prediction of clinical endpoints.
The Pharmacogenomics Journal (2010) 10, 258–266; doi:10.1038/tpj.2010.53
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Introduction
This study is part of the second phase of the microarray quality control (MAQC)
project (MAQC-II).
1 The main design of MAQC-II is laid out in Shi et al.
1 (see also
project summary in Supplemental Material and Supplemental Table S1). This
study aimed at comparing the performance of classifiers for clinical endpoints
that were trained on one-color or two-color microarray data.
Prediction of clinical endpoints from microarray-based gene-expression
measurements can be performed using either of two experimental procedures:
(1) a one-color approach, in which a single RNA sample is labeled with a
fluorophore (such as phycoerythrin, cyanine-3 (Cy-3) or cyanine-5 (Cy-5)) and
hybridized alone to a microarray, or (2) a two-color strategy, in which two
samples (usually a sample and a reference) are labelled with different
fluorophores (for example, Cy-3 and Cy-5) and are then hybridized together
on a single microarray. The resulting data are fundamentally different: while
two-color arrays yield ratios of fluorescence intensities (that is, sample
fluorescence/reference fluorescence), one-color arrays result in absolute
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tonically (if not linearly) related to the abundance of mRNA
species complementary to the probes on the array.
There are pros and cons for both systems. While simplicity
and flexibility of the experimental design might favor one-
color analyses in a clinical setting, two-color measurements
are often believed to be more robust due to the internal
reference, which should cancel out biases related to single
array measurements.
2–4 However, two-color approaches may
be affected by dye bias
5 and, although dye influence can be
corrected for by performing dye-flipped replicate hybridiza-
tions, this strategy substantially augments experimental
costs. Therefore, most researchers refrain from following
such an approach. Moreover, considerable logistic effort has
to be undertaken for two-color analysis, since reference RNA
(or cDNA) must be available in constant quality throughout
the course of the measurements, even if the study may take
years to complete. It is also not easy to choose an
appropriate reference for each application, and there have
been controversial discussions on the use of reference RNAs
with divergent similarity to the sample RNAs of the study.
6,7
While some laboratories stick to mixtures of RNA prepared
from various human tissues (far reference), it may be
sometimes more appropriate to choose a pool of related cell
lines or tissue samples as a source of reference RNA (near
reference), which represent an average over all samples of
the study.
Despite these essential differences, both one-color and
two-color microarray analyses have been widely used with
similarly convincing outcome. However, while consistency
and correlation of primary measurements obtained with
one- and two-color platforms in terms of identifying
differentially expressed genes have been addressed pre-
viously,
8,9 to the best of our knowledge, a systematic
comparison of the classification performance of these two
different techniques has not been reported. Therefore, it is
still unclear if either of these platforms is better suited for
clinical applications that aim at predicting the endpoint of a
disease. Consequently, preference of either experimental
system is at present mostly motivated by criteria that are not
primarily related to the experimental question, such as the
local availability of a specific system, the financial effort of
the intended survey, or presumed but unconfirmed belief of
the superiority of either system.
In this study, we systematically compared for the first time
the power of one-color and two-color measurements to
predict clinical endpoints. To this end, we generated gene-
expression profiles for 478 neuroblastoma tumor samples
using both one-color and two-color microarrays of the same
manufacturer (Agilent Technologies, Waldbronn, Germany).
We have used neuroblastoma here as a model system for our
primary question. While the two-channel data were already
part of the main MAQC-II project, the one-channel data
were generated exclusively for this study using RNA from
the very same tumor samples. Subsequently, eight different
classification algorithms were combined with other proces-
sing steps (for example, normalization, feature selection,
etc.) and applied to predict four different clinical endpoints
for these data sets, resulting in a total of 196 different
models. Classification performance of these models was
then compared between one-color and two-color data by
area under the receiver operating-characteristics curve
(AUC), Matthews correlation coefficient (MCC), accuracy
and root mean squared error (RMSE) as defined by MAQC.
1
Moreover, for models that were trained to choose only a
small number of features for classification, the overlap of the
resulting gene signatures was computed.
Materials and Methods
Sample and RNA preparation
This study comprised a total of 478 different neuroblastoma
tumor samples for which both one-color and two-color
gene-expression profiles were generated. Two-color profiles
were the same as utilized for the MAQC-II (a total of 499
samples, subdivided in training set (n¼246) and test set
(n¼253). For 478 of these samples, single-color profiles were
generated according to a protocol of the same manufacturer
(training set: n¼244 (99.2% overlap) and test set: n¼234
(92.9% overlap). Clinical co-variates of the patient cohort
are given in Supplementary Tables S2 and S3.
Sample and RNA preparation was performed as de-
scribed.
10 In summary, tumor samples were checked by a
pathologist before RNA isolation. Subsequently, samples
with at least 60% tumor content were utilized and total RNA
was isolated from B50mg of snap-frozen neuroblastoma
tissue obtained before chemotherapeutic treatment. After
homogenization of tumor tissue by using the FastPrep FP120
cell disruptor (Qbiogene, Carlsbad, CA, USA) total RNA was
isolated using the TRIzol reagent (Invitrogen, Karlsruhe,
Germany). Integrity of the isolated RNA was assessed using
the 2100 Bioanalyzer (Agilent Technologies) and only
samples with an RNA integrity number of at least 7.5 were
considered for further processing.
Neuroblastoma two-color gene-expression profiles
All two-color gene-expression of the MAQC-II training set
were generated using a customized 2 11K neuroblastoma-
related microarray.
10 Furthermore, 20 patients of the
MAQC-II two-color validation set were also profiled utilizing
this microarray. Two-color profiles of the remaining patients
of the MAQC-II validation set were performed using a
slightly revised version of the 2 11K microarray. For this
version V2.0 of the array, 100 oligonucleotide probes of the
original design were removed due to consistent low expres-
sion values (near background) observed in the training set
profiles, and 200 novel oligonucleotide probes were added.
These minor modifications of the microarray design resulted
in a total of 9986 probes present on both versions of the
2 11K microarray. The experimental protocol did not differ
between both sets, and gene-expression profiles were
performed as described.
10 In summary, 1mg of total RNA of
each tumor sample was linearly amplified and labeled with
Cy3 and Cy5, respectively, using Agilent’s Low-RNA-Input
LinearAmp Kit. Then, 500ng of labeled cRNA was hybri-
dized together with 500ng of reverse color Cy-labeled cRNA
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the 2 11K arrays using Agilent’s in situ Hyb-Kit Plus
following the manufacturer’s protocol. Hybridization was
performed for 17h at 601C in a rotating hyb oven at a speed
of 4 rounds per minute (r.p.m.). Washing was performed at
room temperature following the manufacturer’s protocol.
After scanning, the resulting TIFF-images were processed
using Agilent’s Feature Extraction software (Versions
7.5–9.5.1).
Neuroblastoma single-color profiles
Single-color gene-expression profiles were generated for
478/499 neuroblastoma samples of the MAQC-II dual-color
training and validation set (training set 244/246; validation
set 234/253). For the remaining 21 samples no single-color
data was available due to either shortage of tumor material
of these patients (n¼15), poor experimental quality of the
generated single-color profiles (n¼5) or correlation of one
single-color profile to two different dual-color profiles for
the one patient profiled with both versions of the 2 11K
microarrays. Single-Color gene-expression profiles were
generated using customized 4 44K oligonucleotide micro-
arrays produced by Agilent Technologies (Palo Alto, CA,
USA). These 4 44K microarrays included all probes repre-
sented by Agilent’s Whole Human Genome Oligo Micro-
array and all probes of the version V2.0 of the 2 11K
customized microarray that were not present in the former
probe set. Labeling and hybridization was performed
following the manufacturer’s protocol. In brief, 1mg total
of tumor RNA was linearily amplified and labeled with Cy3
using Agilent’s one-color Quick Amp Labeling Kit following
the instructions of the protocol. Then, 1650ng of Cy3-
labeled cRNA was hybridized on the 4 44K arrays using
Agilent’s High-RPM Gene Expression Hyb Kit. Hybridization
was performed for 17h at 651C in a rotating hyb oven at
10r.p.m. according to the company’s recommendations.
After washing and scanning, resulting TIFF-images
were processed using Agilent’s Feature Extraction software
Version 9.5.1.
The expression profiling data are available within the
in-house and MIAME compliant database iCHIP of the DKFZ
(http://www.ichip.de). This comprises both the one-color as
well as the two-color Agilent gene expression studies and
includes raw as well as processed data. Comprehensive and
actual patient information is associated with the related
experiments, SOPs and protocols for treatment procedures
are included according to the MIAME standard. In addition,
data will be made available through Arrayexpress (Accession
E-TABM-38, E-MTAB-161, E-MTAB-179), and through the
MAQC web site (http://www.fda.gov/nctr/science/centers/
toxicoinformatics/maqc/).
Statistical analysis
Classifiers were trained as described.
1 Classification was
based on microarray data only, clinical data have not been
taken into account. Briefly, data were normalized using the
quantile algorithm from limma.
11 Normalization by the vsn
algorithm yielded similar results (data not shown). For
normalization of the validation set, the training set was used
as reference to ensure that data were on equal scales. Further
details are given in Supplemental Methods.
As performance measures, accuracy (Acc), sensitivity
(Sen), specificity (Spec), Matthews correlation coefficient
(MCC), root mean squared error and AUC of a receiver-
operating characteristics curve were used. For prediction, a
classifier was trained on all available training data using
variables that have been selected in 65% of all cross-
validation runs;
10 where no features were selected (endpoint
N only), this threshold was lowered to 25%.
Sensitivity (SENS) and specificity (SPEC) are given by:
SENS ¼TP=ðTP þ FNÞ
SPEC ¼TN=ðTN þ FPÞ
Where TP, TN, FP and FN are the number of true-positive,
true-negative, false-positive and false-negative samples,
respectively. Accuracy is calculated as
ACCURACY ¼ð TN þ TPÞ=ðTN þ TP þ FN þ FPÞ
The Matthews Correlation Coefficient (MCC) is
MCC ¼
TP TN   FP FN
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ðTP þ FPÞðTP þ FNÞðTN þ FPÞðTN þ FNÞ
p
Root mean squared error is defined as:
RMSE ¼
X
k2testset
ðtk   ykÞ
2
"# 1=2
where tk are the prediction scores (binary or continuous),
the yk are the true class of sample k and summation is over
all samples k in the testset.
The area under an ROC curve
12 is given as:
13
AUC ¼
P
rþ
i   nþðnþ þ 1Þ=2
nþn 
where ri
þ is the rank of the ith positive sample, and n
þ and
n
  are the number of samples in the positive and negative
group, respectively.
Results
Data sets for comparative analysis
Two-color gene expression profiles for a total of 499
neuroblastoma (NB) tumor samples were provided to the
MAQC-II consortium as a benchmark set for evaluation of
classification workflows.
1 These profiles were generated as
dye-flipped replicates using a 2 11K oligonucleotide
microarray manufactured by Agilent Technologies (Santa
Clara, CA, USA).
To allow for an in-depth comparison of the classification
performance of one-color vs two-color microarray measure-
ments, we additionally performed one-color gene-expres-
sion profiling for 478/499 of the afore-mentioned
neuroblastoma tumor samples. Following the basic design
of the MAQC-II study, in which two-color profiles of
neuroblastoma samples were divided into a training
set (n¼246) and an approximately equal-size-blinded
validation set (n¼253), one-color profiles of the same
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two-color training set samples (99% overlap) and 234/253
MAQC-II NB validation set samples (92.5% overlap). The
reasons for lacking one-color profiles were: (i) shortage of
RNA or tumor material (n¼15), (ii) poor experimental
quality for one-color profile (n¼5) and (iii) correlation of
one one-color profile to two different two-color profiles for
one patient of the validation set who had been profiled with
different versions of the 2 11K microarray (see Methods
and Supplementary Tables S2 and S3). For the comparative
analysis, only those 478 samples that had been profiled with
both platforms were considered. It is interesting to note that
Agilent Technologies no longer manufactured the 2 11K
design used for generation of the two-color profiles. For this
reason one-color profile had to be generated utilizing a
4 44K oligonucleotide microarray manufactured by the
same company. This higher-density 4 44K microarray
comprised all probes from the 2 11K oligonucleotide
microarray. Thus, data from the resulting gene-expression
profiles of both platforms was restricted to a common set of
9986 probes represented by both designs to allow for a
reasonable comparison of classification performance of one-
or two-color measurements. It is interesting to note that
some parameters of the labelling and hybridization proce-
dure had to be adjusted for the higher-density 4 44K
format thus resulting in slight differences between the one-
color and two-color experimental protocols (details are
indicated in the Methods section and summarized in
Supplementary Table S4).
Comparison of cross-validated classification performances
(training set)
Following the basic approach of the MAQC-II study,
classifiers from both one-color and two-color gene-expres-
sion measurements sets were generated to predict all four
clinical endpoints that had been defined for the neuroblas-
toma data set (endpoints J, K, L and M, Table 1). To allow for
a comprehensive comparison of the prediction performance
of both experimental systems, eight different algorithms
were applied to both data sets, including discriminant
analysis, generalized linear models, logistic regression (LR),
prediction analysis of microarrays (PAM
14), partial least
squares (PLS), partition tree (PT), radial basis machine (RBM)
and support vector machines in combination with recursive
feature elimination (SVMþRFE
15). Combination of these
algorithms with other processing steps (for example,
normalization, feature selection, etc.) resulted in a total of
196 different classification models that were applied to both
platforms and were compared with respect to classification
performance (all results are summarized in Supplementary
Table S5).
Cross-validated classification performance of both plat-
forms was measured by MCC, a balanced measure composed
of sensitivity and specificity,
16 AUC, RMSE and accuracy.
Then, values of these parameters for classifiers built from
one-color data were plotted against values observed for
classifiers built from two-color data (Figure 1, Supplemen-
tary Figure 1). As indicated in Figure 1, cross-validated
predictive performance varied primarily between the differ-
ent endpoints. This result was expected as two endpoints
were introduced as positive (patients’ sex, endpoint L) and
negative (random selection, endpoint M) control endpoints,
respectively. These endpoints were further characterized by a
balanced group distribution of the samples (Table 1). For the
positive endpoint L, nearly perfect classification perfor-
mance was reached (MCC: 0.87–0.95, mean MCC: 0.93;
AUC: 0.96–0.98, mean AUC: 0.97) while results for the
negative endpoint M were close to random prediction
Table 1 Number of samples available for training and validation, and number of positive or negative cases for each clinical
endpoint
Endpoint
code
Endpoint description Training set Validation set
Number of
samples
Positives
(P)
Negatives
(N)
P/N
Ratio
Number of
samples
Positives
(P)
Negatives
(N)
P/N
Ratio
J OS_MO—overall survival milestone
outcome (OS, 900-day cutoff)
236 22 214 0.10 161 37 124 0.30
K EFS_MO—event-free survival
milestone outcome (EFS, 900-day
cutoff)
237 59 178 0.33 174 78 96 0.80
L NEP_S—newly established parameter
S. *The actual class label is the sex of
the patient and unaware to data
analysis teams. Used as a ‘positive’
control endpoint.
244 144 100 1.44 231 133 98 1.36
M NEP_R—newly established parameter
R (NEP_R). **The actual class label is
randomly assigned and unaware to
the data analysis teams. Used as a
‘negative’ control endpoint.
244 143 101 1.41 231 132 99 1.33
Lower number of samples available for endpoints EFS_MO and OS_MO is because of missing values for these endpoints.
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The Pharmacogenomics Journal(MCC:  0.09–0.11, mean MCC:  0.04; AUC: 0.44–0.57,
mean AUC: 0.48). In contrast, endpoints J (overall survival)
and K (event-free survival) were true clinical endpoints with
medium classification difficulty.
1 Results for endpoint J
ranged from MCC values of  0.02 to 0.41 (mean 0.19) and
from AUC values of 0.76–0.88 (mean 0.84), respectively.
Results for endpoint K yielded MCC values ranging from
0.14 to 0.50 (mean 0.37) and AUC values of 0.70–0.90 (mean
0.85). As shown in Table 1, the latter two endpoints present
highly unbalanced distribution among the samples.
Second, as shown in Figure 1, minor differences in
classification performance were observed between the
different classification models applied to the data sets.
However, as the most important finding with respect to the
objective of our study, no substantial difference in classifica-
tion performance was observed between the two different
experimental platforms as indicated by a remarkably high
correlation between one-color and two-color performance
observed for all four classification criteria (Figure 1,
Supplementary Figure 1). Furthermore, to assess the robust-
ness of predictive models from one-color and two-color
measurements, the variance of the performance was esti-
mated by calculating the s.d. of the performance metrics
MCC, AUC, RMSE and accuracy from repeated runs of
the algorithms. As expected, s.d. depended on both the
clinical endpoint and the classification algorithm used
for prediction. However, apart from these effects, we
also observed that the s.d. of performance metrics was
consistently lower when classifiers were trained on two-
color data. This observation is illustrated in Figure 2, in
which s.d. of AUC are indicated for different endpoints for
each of the classification algorithms. The only exception is
classifiers for endpoint L using LR, PAM, PLS, RBM or
SVMþRFE as classification algorithms (Figure 2). Thus, the
variability of the prediction was in general lower when
classifiers were trained from two-color data, whereas the
average estimate of predictive performance was not different
(Figure 1).
Comparison of classification performance on the validation set
After internal validation, classifiers of each algorithm were
trained on the entire training set using optimized para-
meters and—if applicable—a set of features frequently
selected in cross-validation. Subsequently, the resulting final
classifiers were applied to predict class labels for the
validation set of samples for all endpoints. Again, classifica-
tion performance was assessed by calculating MCC, AUC,
RMSE and accuracy.
In line with the cross-validated results observed in the
training set data, classification performance differed most
prominently with respect to the clinical endpoint and with
respect to the applied classification algorithm. In contrast,
equivalent overall performance metrics resulted from one-
color and two-color data measurements, thereby substan-
tiating that this factor does not significantly influence
the classification performance. As an exception, a slight
Figure 1 Comparison of results classification from one-color vs two-color training data using 10 iterations of 5  cross validation. The data shown
are the mean results from 10 independent runs. A set of 9986 common probes and 244 samples was used to train the classifiers. For each endpoint,
eight different classification methods were applied, namely discriminant analysis, general linear model selection, logistic regression, partial least
square (PLS), partition tree, radial basis machine, prediction analysis of microarrays (PAM) and support vector machines plus recursive feature
elimination (SVMþRFE) were selected for prediction. Values for MCC (a) and AUC (b) of the prediction results using one-color and two-color data
are plotted against each other. Endpoints are coded by color: OS_MO (endpoint J), red; EFS_MO (endpoint K), green; patient’s sex (endpoint L),
blue; random classes (endpoint M), orange.
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color data was noted for classifiers built on PLS and LR, for
which this effect was detectable for all endpoints (Figure 3,
Supplementary Figure 2). Apart from that, we also observed
marginally higher performance values for models built on
PT and one-color data for the negative endpoint M.
However, as illustrated in Supplementary Figure 1, these
effects were clearly restricted to these models and the
combination of specific models with certain endpoints,
respectively. Thus, the putative higher prediction perfor-
mance of the one-color data was not a general finding but
rather a specific effect occurring only with these algorithms,
or with a combination of specific algorithms and the chosen
feature selection method.
Overlap of resulting gene signatures
Finally, models that were built on either PAM or SVM-RFE
were also compared with respect to their resulting gene
signatures. As a general observation, classifiers derived from
one-color data tended to include fewer features than those
from two-color data in our study (Supplementary Table S5).
Apart from that, it was noted that features selected in
training from one- or two-color data showed only little
overlap (Figure 4a) for the clinical endpoints. Interestingly,
we found that the degree of overlap decreased with
increasing difficulty of the predicted endpoint. Hence, for
the positive endpoint L (patients’ sex), three of four
approaches concurrently selected a total of two identical
features (Figure 4b). Moreover, the four features selected by
the remaining approach also comprised these two features
(overlap 50%, Figure 4b). Intriguingly, the features recur-
rently selected for classification of this endpoint,
X (inactive)-specific transcript (XIST) and ribosomal protein S4,
Y-linked 1 (RPS4Y1), are known to be expressed in a highly
sex-specific manner. XIST is a non-coding RNA involved in
silencing of the second X chromosome in female cells,
17 and
RPS4Y1 is a ribosomal protein encoded by Y chromosome.
Thus, with respect to this endpoint, both systems not only
performed equivalently well with only a very small number
of features, but also demonstrated similar potential to
identify features with mechanistic relevance, as indicated
by the biological function of the selected candidates.
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Figure 2 Standard deviation of AUC for different endpoints for each of the classification algorithms as assessed from repeated runs of the
cross-validation.
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In this study, we conducted a systematic comparison of the
classification performance resulting from one- and two-
color gene-expression measurements of a considerable
number of 478 clinical samples. From these, a large number
of classification models was generated to predict four
endpoints defined for the MAQC-II study and performance
was assessed by the metrics MCC, AUC, RMSE and accuracy
both for internal and external validation. Cumulatively, our
analysis indicates a largely equivalent overall performance
of both platforms, thereby suggesting that the choice of a
one-color or of a two-color platform does not need to be a
primary factor in decisions regarding experimental micro-
array design in classification studies.
To allow for warranted conclusions from our calculations,
gene expression profiling was performed using the one- and
two-color platform from the same manufacturer, Agilent
Technologies. Furthermore, since two different microarray
designs (2 11K vs 4 44K) had to be used for this study,
predictive models were built on a set of roughly 10000
probes common to both designs. Although every effort was
made to conduct the analyses comprised in this study as
similar as possible, some minor differences in the experi-
mental procedures were inevitable. First, because of a
change to a higher density microarray design (4 44k) for
the one-color profiles, the protocols differed slightly, mainly
with respect to the hybridization temperature (601C for
two-color, 651C for one-color, see Supplementary Table 3).
Second, two-color samples were measured as dye-swap
replicates yielding two profiles per patient, whereas single-
color arrays where performed without replications. A third
factor was the standardization of the two-color data relative
to a signal from a reference channel, which is intrinsic to the
method. Despite these differences, classification perfor-
mance was observed to be highly comparable as measured
by repeated internal 5  cross validation, thereby under-
lining the validity of our approach. A marginally higher
robustness of classifiers trained from two-color data was
suspected based on the lower variance of performance
measures observed with two-color measurements. However,
considering the fact that two-color data were generated as
dye-flipped replicates (resulting in two measurements per
patient), this observation can be explained by the higher
degree of replication in the two-color data set. Alternatively,
measurement against an internal reference on the same chip
could have resulted in a stabilization of the two-color data.
Similarly, predictive performance on an independent
validation also was comparable between one-color
and two-color measurements. However, a slightly higher
performance of classifiers trained on one-color data was
observable for three of the eight classification algorithms
used, namely PLS, LR and for endpoint M also PT. This
finding could point to a tendency of overfitting of these
classifiers when trained on two-color data. However, it
should be noted that a higher classification performance
Figure 3 Comparison of classification results from one-color vs two-color data on an independent validation set. A set of 9986 common probes and
244 samples was used to train the classifiers. Eight classification methods, discriminant analysis, general linear model selection, logistic regression,
partial least square (PLS), partition tree, radial basis machine, prediction analysis of microarrays (PAM) and support vector machines plus recursive
feature elimination (SVMþRFE) were selected for prediction. MCC (a) and AUC (b) of the prediction results using one-color and two-color data are
plotted against each other. Endpoints are coded by color: OS_MO (endpoint J), red; EFS_MO (endpoint K), green; patient’s sex (endpoint L), blue;
random classes (endpoint M), orange.
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one-color data) rather indicates a limited suitability of that
classifier. Alternatively, the observation of higher perfor-
mance of some models with one-color data might be related
to the feature selection algorithms used in combination
with these algorithms. As the number of features selected for
classification was generally lower for classifiers generated
from one-color data, it can be hypothesized that one-color
gene-expression measurements were less noisy and more
stable as compared to log-ratio data from two color arrays.
However, since this effect was neither visible with other
classification algorithms nor in the internal validation by
cross-validation, we conclude that the observed differences
in performance do not indicate a general effect that results
from the choice of the platform.
With respect to the varying degrees of overlap observed
for the selected signature genes, our finding that the
potential overlap of features decreases with increasing
difficulty of the predicted endpoint is also in line with
results of the MAQC-II main study, in which it was shown
that feature list stability is inversely correlated with end-
point difficulty.
1 However, the higher degree of replication
underlying the two-color data set clearly influenced feature
selection in our study, thereby making it difficult to draw
definite conclusions from this analysis. In addition, over-
lapping genes do not appear to be a true indicator of
performance, since it has been shown clearly that differing
sets of genes may be derived from a single data set and
perform equally well in terms of classification.
18 Yet, the fact
that both platforms identified features with biological
relevance with high overlap for an easily predictable
endpoint (L) appears to further underscore the equivalent
potential of both approaches.
Neuroblastoma was used in this study as a model system
to address our primary question, the difference or similarity
in performance of classifiers trained on one-color or two-
color microarray-based gene expression measurements.
While similar studies on other tumor entities have not
been performed so far, it is reasonable to believe that the
results can be extrapolated to other entities with similar
approaches, that is, prediction of a binary clinical endpoint
based on high-dimensional gene expression measurements,
provided that microarray-based classification allows at all
for such prediction.
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Abbreviations
AUC area under the receiver operating-characteristics curve
DAT data analysis team
DEG differentially expressed genes
LR logistic regression
MAQC microarray quality control
MAQC-I microarray quality control phase I on technical
performance
MAQC-II microarray quality control phase II on predictive
modeling
MCC Matthews correlation coefficient
NB neuroblastoma
PAM prediction analysis of microarrays
PLS partial least square
PT partition tree
RBWG regulatory biostatistics working group of MAQC-II
RBM radial basis machine
RFE recursive feature elimination
RMSE root mean-squared error
SVM support vector machines
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